Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
A comparative trial where all patients will receive daily doses of tacrolimus (TAC) until day
+60 when tapering will begin, in the absence of graft-versus-host disease (GVHD), and
discontinued by day +180. In addition patients will be randomized to methotrexate (MTX) or
mycophenolate mofetil (MMF) and again, in the absence of GVHD, a tapering schedule will begin
on day +240 and be completed on day +360. Doses will be adjusted to maintain blood levels.
Phase:
N/A
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute